Heat-Related Deaths Among Crop Workers -United States, 1992-2006
Workers employed in outdoor occupations such as farm ing are exposed to hot and humid environments that put them at risk for heat-related illness or death. This report describes one such death and summarizes heat-related fatalities among crop production workers in the United States during 1992-2006. During this 15-year period, 423 workers in agricultural and nonagricultural industries were reported to have died from exposure to environmental heat; 68 (16%) of these workers were engaged in crop produc tion or support activities for crop production. The heatrelated average annual death rate for these crop workers was 0.39 per 100,000 workers, compared with 0.02 for all U.S. civilian workers. Data aggregated into 5-year periods indicated that heat-related death rates among crop workers might be increasing; however, trend analysis did not indi cate a statistically significant increase. Prevention of heatrelated deaths among crop workers requires educating employers and workers on the hazards of working in hot environments, including recognition of heat-related illness symptoms, and implementing appropriate heat stress management measures.
Information for the illustrative case described in this report was collected by the Agricultural Safety and Health Bureau of the North Carolina Department of Labor. For the nationwide analysis, fatality data were obtained from the Bureau of Labor Statistics (BLS) Census of Fatal Occu pational Injuries (CFOI) (1) .* A heat-related death was identified in CFOI as an exposure to environmental heat (BLS Occupational Injury and Illness Classification Sys tem [OIICS] event/exposure code 321), with the nature of * For this report, CDC used a CFOI research file provided by BLS, which excluded deaths in New York City. Because of confidentiality restrictions, individual case information from the CFOI data cannot be reported; information for the case described in this report was obtained solely from the North Carolina Department of Labor field investigation.
injury attributed to effects of heat and light (OIICS nature code 072). A crop worker death was indicated where the industry in which the decedent worked was crop produc tion or support activities for crop production. † Fatality rates were calculated as an average annualized rate per 100,000 workers during the 15-year study period for civilian noninstitutionalized workers aged >15 years. The numera tor was the total of all fatalities during the 15-year period; the denominator was the total of the annual average worker population during the same period. Estimates of the num ber of workers employed were derived from the U.S. Cur rent Population Survey (CPS) (2) . § To examine trends in fatality rates during the study period, data were aggregated in 5-year periods because the numbers of fatalities for sev eral individual years in the study period were too low to meet BLS publishing criteria. Poisson regression was used to estimate confidence intervals for these aggregate rates.
Case Report
In mid-July 2005, a male Hispanic worker with an H-2A work visa (i.e., a temporary, nonimmigrant foreign worker hired under contract to perform farm work) aged 56 years was hand-harvesting ripe tobacco leaves on a North Caro lina farm. He had arrived from Mexico 4 days earlier and was on his third day on the job. The man began work at approximately 6:00 a.m. and took a short mid-morning break and a 90-minute lunch break. At approximately 2:45 p.m., the employer's son observed the man working slowly and reportedly instructed him to rest, but the man contin ued working. Shortly thereafter, the man's coworkers noticed that he appeared confused. Although the man was combative, his coworkers carried him to the shade and tried unsuccessfully to get him to drink water. At approximately 3:50 p.m., coworkers notified the employer of the man's condition. At 4:25 p.m., the man was taken by ambulance to an emergency department, where his core body tem perature was recorded at 108°F (42°C) and, despite treat ment, he died. The cause of death was heat stroke. On the day of the incident, the local high temperature was approximately 93°F (34°C) with 44% relative humidity and clear skies. The heat index was in the range of 86°-101°F (30°-38°C) at mid-morning and 97°-112°F (36°-44°C) at mid-afternoon. ¶ Similar conditions had occurred during the preceding 2 days.
The man had been given safety and health training on pesticides but nothing that addressed the hazards and pre vention of heat-related stress. He reportedly only spoke Spanish. Fluids, such as water and soda, were always avail able to the workers in the field; however, whether the man drank any of these fluids is unknown.
46% of the decedents; however, during 2003-2006,
Editorial Note: During 1992-2006, a total of 68 crop approximately 20 (71%) of the 28 deceased crop workers workers died from heat stroke, representing a rate nearly 20 times greater than for all U.S. civilian workers. The majority of these deaths were in adults aged 20-54 years, a ** Data are not reported by sex because they do not meet BLS publication criteria.
population not typically considered to be at high risk for heat illnesses (3) . In addition, the foreign-born workers.
1992-2006
Persons who work outside in hot and related mortality and morbidity.
Industry category
Heat-related illnesses range from proportion of heat-related deaths § Annual national average estimates (totaled for 15 years) of employed civilians aged >15 years, among foreign-born workers indicates based on the Current Population Survey. Monthly total number of workers are monthly national average estimates. State total number of workers are annual state average estimates. Numbers that training and communications reare rounded to thousands.
garding the risk for heat-related ill ¶ Labor force data not available. ** Includes crops such as cotton, tobacco, sugarcane, and hay; excludes oilseeds and grains.
nesses should be provided in the workers' native language. 5-year period * Per 100,000 workers. Rates calculated using annual national average estimates of employed civilians aged >15 years based on the Current Population Survey. † 95% confidence interval for fatality rate.
Guidance to help agricultural employers establish a heatillness prevention program is available from CDC and the U.S. Environmental Protection Agency (4, 5) . In addition, the Department of the Army and Air Force has published a technical bulletin that provides strategies for employers to control heat stress (6) . Heat-related safety materials in English and Spanish are available from several other sources, including the California Division of Occupational Safety and Health † † and the North Carolina Department of Labor. § § California and Washington state have recently enacted regulations requiring that employers take action to prevent heat-related illnesses and deaths among their work ers, including providing training to supervisors and work ers and ensuring the availability of fluids (7, 8) . These regulations were prompted by deaths and illnesses in both states in recent years.
The findings in this report are subject to at least four limitations. First, certain fatality rates had to be calculated as average annualized rates for the entire 15-year study period because small numbers prevented publication according to BLS publishing criteria. This aggregation obscured variability between years. Second, CPS estimates likely underestimated the number of crop workers because of the seasonal nature of the work and because the CPS relies on stable residences for sequential interviews. An underestimate of the worker population would have resulted in an overestimation of the fatality rates. Third, heatrelated deaths were likely underreported because heat stroke was not recognized at the time of death, was not indicated as a contributing factor on the death certificate (3), or was not recognized by the state agencies as meeting the case definition for an injury-related death in CFOI. Finally, the fatality rates for 5-year periods were based on small num bers with large confidence intervals, and the data do not allow an assessment of whether increased numbers over time might be a reflection of increased awareness and reporting.
The illustrative case described in this report and another case previously reported by CDC (9) suggest that some employers might not have heat stress management programs in place. Agricultural employers should develop and imple ment heat stress management measures that include 1) training for field supervisors and employees to prevent, rec ognize, and treat heat illness, 2) implementing a heat acclimatization program, 3) encouraging proper hydration with proper amounts and types of fluids, 4) establishing work/rest schedules appropriate for the current heat indi ces, 5) ensuring access to shade or cooling areas, 6) moni toring the environment and workers during hot conditions, and 7) providing prompt medical attention to workers who show signs of heat illness (5, 6, 10) . Employers and workers should be vigilant for signs of heat illness, not only in them selves but in their coworkers, and be prepared to provide and seek medical assistance. (1, 2) . Since 1964, the Advisory Commit tee on Immunization Practices (ACIP) has recommended influenza vaccination of all persons with asthma because of the higher risk for medical complications from influenza for those persons (3, 4) . Influenza vaccination coverage of persons with asthma varies by age group and remains below Healthy People 2010 targets of 60% coverage of per sons aged 18-64 years with high-risk conditions (14-29c) and 90% of all persons aged >65 years (14-29a) (5-7). Influenza vaccination rates of children and older adults with asthma have not been well studied. Using 2006 National Health Interview Survey (NHIS) data, this report provides the first examination of influenza vaccination rates and related factors across a national sample of persons with asthma aged >2 years. The results indicated that 36.2% received influenza vaccination during the 2005-06 influ enza season. Vaccination rates remained below target levels among all subgroups examined, including those reporting the greatest number of health-care visits in the past 12 months. The results of this study indicate that influenza vaccination coverage of all persons with asthma can be improved by increasing access to health care and using opportunities for vaccination during health-care visits.
NHIS is an ongoing, nationally representative, in-person household interview survey of the civilian, noninstitutionalized population of the United States. (5) . Because diagnoses of asthma in children aged <2 years are considered unreliable, and to be consis tent with other reports, the <2 years age group was excluded from this report (6) .
To Table 2 ).
The likelihood of receiving an influenza vaccination increased with increasing numbers of health-care visits, defined as a visit to a doctor's office, clinic, or other place of health care, but not counting hospitalizations, emergency department visits, dental or home visits, or telephone calls (Table 3 ). Coverage ranged from 17.6% in persons with asthma reporting one visit or less to 50.8% in those reporting 10 or more visits. Stratified by number of healthcare visits, influenza vaccination coverage was significantly higher among persons with asthma than among those without for each stratum, except for the 6-9 health-care visits stratum. Stratified by available measures of asthma Editorial Note: This report presents the first estimates of influenza vaccination coverage in the United States among the civilian, noninstitutionalized population of persons with asthma and reinforces the need to increase vaccination throughout this at-risk population. Health-care visits pro vide an opportunity for vaccination, but even among per sons with the highest number of visits, nearly half remained unvaccinated in the 2005-06 influenza season. Even so, access to health care is an important factor associated with receiving influenza vaccination. Persons with asthma who had health insurance had a greater rate of influenza vacci nation than did those who lacked insurance. Likewise, the vaccination rate for persons with asthma who had a usual place for health care was significantly greater than the rate for those who did not have a regular place for health care. After the vaccine shortage of the 2004-05 influenza sea son, vaccination coverage of persons with asthma in 2005-06 failed to improve among households with the lowest incomes, among persons without health insurance, and among persons without a regular place for medical care, emphasizing the need for interventions that include the medically underserved.
During the 2005-06 influenza season, the oldest age groups (50-64 years and >65 years) had the highest vacci nation coverage. Influenza vaccination is recommended for both age groups, regardless of asthma status, because the influenza-related death rate increases sharply among older adults (3). In February 2006, ACIP recommended that all children aged 24-59 months be vaccinated against influ enza, regardless of risk status. Examination of the 2007 NHIS data could determine whether the expanded recom mendation affected coverage among the subset of children with asthma, who already had been recommended for vac cination under previous guidelines. Because ACIP voted in February 2008 to recommend influenza vaccination for all children, data soon will be available to also study the effects on coverage for older children.*
The findings in this report are subject to at least three limitations. First, the sample size of the survey (34,112 adults and children, 2,700 of whom reported having cur rent asthma) limits reliable identification of patterns among subgroups of persons with asthma potentially of interest but smaller in number than the subgroups examined here. Second, determination of vaccination status in NHIS is made by self-report, which introduces recall bias and likely overestimation of vaccination rates (8) . Finally, NHIS does not ascertain whether a child received a second vaccine dose, as is recommended by ACIP for children aged 6 months to 8 years who previously have not received the influenza vac cination; therefore, NHIS overestimates full coverage for this age group (3).
The findings in this report emphasize the need for mea sures to uniformly increase influenza vaccination rates among persons with asthma. Interventions that target patients, health-care access, and health-care providers have demonstrated benefits in similar settings and should be implemented to improve influenza vaccination coverage. Such interventions include automated reminders, stand ing orders, multicomponent educational programs, reduc tion of travel distances or out-of-pocket vaccine costs, and provider performance feedback (9) . Persons with inadequate access to health care and those treated at multiple facilities would be less likely to miss opportunities for vaccination if they consistently sought care at a single medical facility. That continuity of care could reduce the diffusion of responsibility that occurs when patients are treated at mul tiple health-care facilities (10) . Providing vaccination through at least January and February of the influenza sea son can further reduce missed opportunities for effective vaccination of persons in this group at high risk. 
Recommendations from an Ad Hoc Meeting of the WHO Measles and Rubella Laboratory Network (LabNet) on Use of Alternative Diagnostic Samples for Measles and Rubella Surveillance
Laboratory confirmation of measles and rubella is an important component of disease surveillance in all settings. Because the use of clinical diagnosis for surveillance is un reliable, case-based laboratory confirmation of disease is critically important in settings with measles or rubella elimi nation goals. The World Health Organization (WHO) Measles and Rubella Laboratory Network (LabNet) was established in 2000 to provide a standardized testing and reporting structure and a comprehensive, external qualityassurance program (1) . LabNet currently consists of 679 laboratories serving 166 countries. However, measles and rubella surveillance remains incomplete in certain areas because of difficulties with the collection and transport of serum specimens. Recently, LabNet evaluated two alterna tive sampling approaches to serum samples, the use of dried blood spots (DBS) and oral fluid (OF) samples. Both of these approaches have potential to be useful tools for measles and rubella control programs. In June 2007, WHO con vened an ad hoc meeting in Geneva, Switzerland, to review available data and provide recommendations on use of DBS and OF samples for measles and rubella diagnostics. Attendees included LabNet staff members and scientists who had been conducting studies to evaluate use of these alternative diagnostic samples. The attendees concluded that 1) although serum-based diagnostics remain the "gold standard," the use of these two alternative sampling tech niques would not adversely affect routine measles and rubella surveillance and might enhance surveillance; 2) regions in the elimination phase* that already have established serum-based testing for rash illness surveillance would not likely benefit from converting to DBS or OF sampling methods, except in special circumstances; and 3) DBS or OF sampling are viable options for measles and rubella surveillance in all regions, especially where patients might resist venipuncture for blood collection, or where special challenges exist with transport or refrigeration of diagnostic samples.
Background on Use of Alternative Diagnostic Samples
Conventional laboratory confirmation of suspected cases of measles and rubella is based on the detection of virusspecific immunoglobulin M (IgM) in a single serum sample collected soon after the onset of symptoms (2) . In addi tion, detection of viral RNA by reverse transcriptionpolymerase chain reaction (RT-PCR), usually in a throat swab or urine sample, and subsequent genotyping of strains is valuable for diagnosis and molecular epidemiology (2) . Accurate laboratory results for detection of IgM and viral RNA are dependent on proper collection, processing, ship ment, and storage of clinical samples and use of accurate tests performed by a proficient laboratory. However, col lection of blood samples by venipuncture, particularly from children, can be a challenge, and the sustained refrigera tion required for diagnostic samples during transport is not always achievable. In these situations, alternatives to serum collection can be useful.
DBS has been used for various epidemiologic studies for the detection of measles-and rubella-specific IgG and IgM antibodies and viral RNA (3) (4) (5) . Antibody and viral RNA are sufficiently stable on DBS at <98.6°F (<37.0°C) to allow this sample collection method to be used for case confirmation or molecular epidemiology in areas where sample refrigeration is not feasible. OF has been used in similar studies and for the national measles, mumps, and rubella (MMR) surveillance program in the United King dom (UK) for approximately 10 years (6,7). OF is easy to collect, and collection is more acceptable to the population (6), thereby enabling health-care workers to obtain more complete sampling for suspected cases.
Evaluations Comparing Alternative Diagnostic Samples with SerumBased Diagnostics
Since 2001, LabNet reference labo ratories in Australia, Cote d'Ivoire, Netherlands, Turkey, Uganda, the UK, and the United States have been working to 1) determine IgM and RNA stability in DBS and OF samples and 2) optimize the methods for IgM antibody assay and pro tocols for RNA detection in DBS and OF samples (8) (9) (10) . This work has provided data on sensitivity and speci ficity of OF and DBS samples compared with serum and also has identified logistic challenges in implementing alternative sampling techniques. Three different types of data were available for review during the ad hoc meeting. First, beginning in 2001, LabNet laboratories conducted stud ies that collected OF, DBS, and corresponding serum samples from persons with suspected measles or rubella during outbreaks and tested the samples for the presence of measles-or rubella-specific IgM antibodies. Second, LabNet reviewed data from the MMR surveillance program in the UK, where 1,000-3,000 OF samples have been col lected annually during the past decade. Third, LabNet re viewed data from seven countries in the WHO African Region that used DBS sampling methods for routine measles and rubella surveillance during [2005] [2006] [2007] . DBS was either the only sample collected (Sierra Leone) or was collected in conjunction with routine serum collection (Burkina Faso, the Democratic Republic of Congo, Ethio pia, Ghana, Senegal, and Zambia). Standard protocols for sample collection and laboratory testing recommended by LabNet were used (2) .
Data from all three sources indicated that the sensitivity and specificity of DBS and OF for detecting measles and rubella virus-specific IgM parallels that of serum; however, a moderate decline in sensitivity for detecting rubella virusspecific IgM in OF during the first 4-5 days after disease onset was observed (Figures 1 and 2 ; Table) . Detection of RNA in serum and DBS was shown to be possible with nested or real-time RT-PCR (but not conventional RT-PCR) if samples are collected within 5-7 days after rash onset. This procedure has proven invaluable for collecting viral sequence information where urine or throat swabs were not available. In the MMR surveillance program in the UK, using OF, the rate of measles RNA detection by nested RT-PCR ranged from 80% to 90% when collected during the first week after rash onset, and reached 50% at 3-4 weeks after rash onset. Conventional RT-PCR was sensitive for up to 2 weeks after rash onset, but was still considered useful. For rubella, testing for both IgM and RNA in OF samples substantially increased the sensitivity of surveil lance for confirming cases during the first 4-5 days after rash onset, when many rubella cases are not yet IgM posi tive. Results of evaluations comparing OF and DBS with serum sampling indicated that OF and DBS sampling have a potential role in improving measles and rubella surveil lance. Compared with serum collection, these sampling procedures provide:
• Equivalent sensitivity and specificity for specific IgM detection, although moderately reduced sensitivity for detecting rubella virus-specific IgM in OF samples.
• Simplified sample collection, although training is required.
• Good acceptance by patients, because DBS avoids venipuncture and OF is noninvasive.
• Stability without refrigeration for periods of up to 7 days (OF) or longer (DBS).
• Equivalent cost for collection, extraction, and testing.
• Potential to substantially reduce transport costs through avoiding refrigeration.
• Ability to detect both specific IgM and RNA in the same sample. OF can extend the opportunity for RNA detection after rash onset.
• Equivalent sensitivity and specificity for IgG detection and con sequent versatility for use in seroepidemiology studies. However, use of OF and DBS sampling also has some disadvantages compared with serum collection, in particular:
• Collection devices are not commonly available and • Extraction procedures for DBS and OF require more would need to be provided to health-care facilities by time of technicians. the surveillance program.
• External quality-assurance programs, such as those cur • Volume of DBS might be inadequate unless staff are rently required for testing of serum, have yet to be fully trained in sample collection.
established for OF and DBS. 
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Recommendations
Having considered the evidence described in this report, participants in the ad hoc meeting made the following recommendations.
No single alternative sampling technique has been shown to be optimal for surveillance under every circumstance, and serum should still be considered the "gold standard" for IgM detection. However, DBS and OF sampling tech niques are viable options for measles and rubella surveil lance (5-10), especially where challenges with specimen transport or refrigeration exist or where patients might resist venipuncture. Alternative sampling techniques would not adversely affect routine measles and rubella surveillance (provided adequate training and resources are provided) and might enhance surveillance through:
• More acceptable noninvasive methods (OF).
• Reduced transport costs (DBS and OF).
• Enhanced ability to conduct molecular surveillance (OF and DBS RNA).
• Enhanced sensitivity of rubella case confirmation dur ing the first 4-5 days after rash onset (OF RNA).
• Offering a confirmatory option for questionable serum IgM results during the early stage of disease for both measles and rubella (OF RNA). Regions in the elimination phase that already have established a serum-based rash illness surveillance system would not likely benefit from changing to DBS or OF sam pling methods except in special circumstances, such as in settings where:
• Timely specimen transport from remote or difficult to-access areas to the laboratory conducting the sero logic analysis is especially difficult.
• Collection of OF in addition to serum might improve efficiency of case identification and virologic surveil lance by enabling detection of viral RNA from disease onset. Despite the increased number of false-positive results, testing with the noninvasive oral fluid specimens was popu lar with clinic patients and more convenient for staff mem bers; therefore, the NYC DOHMH continued offering oral fluid rapid HIV testing while attempting to minimize the adverse effects of false-positive test results. In late Decem ber 2005, a revised strategy was implemented at the clinics by continuing to offer oral fluid rapid tests but immedi ately following reactive oral fluid tests with a second OraQuick test on finger-stick whole-blood specimens. Both test results were documented in the medical record. Coun selors continued to explain to patients that any reactive rapid tests required Western blot confirmation but also emphasized that discordant oral fluid and whole-blood test results were likely to be false positive. By During this second instance of increasing numbers of false-positive oral fluid tests, the clinics continued offer ing immediate follow-up finger-stick whole-blood rapid tests for all patients with reactive oral fluid tests. The usefulness of the NYC DOHMH policy was affirmed by the strong correlation between results from whole-blood rapid tests and confirmatory Western blot tests. During December 2005-May 2008, 1,720 patients had reactive oral fluid rapid tests, and definitive Western blot results were recorded for 1,664 (Figure 2 ). Missing Western blot results (24 patients) and inconclusive Western blot results (32 patients) were excluded from additional analysis. Of these 1,664 patients, 1,194 also provided a finger-stick specimen; 850 (71.2%) had a reactive finger-stick test, of whom 840 (98.8%) were positive by Western blot. Only one (0.3%) of 344 patients with a reactive oral fluid and negative finger-stick whole-blood rapid test was positive by Western blot.
Implications for Measles and Rubella Surveillance in the United States
Despite the NYC DOHMH policy that STD clinics should retest using whole-blood specimens after reactive oral fluid tests, 550 patients with reactive oral fluid results did not receive a finger-stick test. † For 80 of these patients, the test was ordered but not completed; of these, 77 (96.3%) had a positive serum Western blot result. A total of 470 (28.2%) patients with reactive oral fluid tests declined the finger-stick test. Of these, 455 (96.8%) were confirmed positive by serum Western blot, compared with 850 (71.2%) of the 1,194 patients who agreed to a finger-stick test. Additional investigation indicated that 29% of patients with a reactive oral fluid test result who then declined the finger-stick test had been reported previously as HIV-positive to the local HIV/AIDS Reporting System, compared with 21% of patients who agreed to a follow-up finger-stick test. † Before patients were examined by a clinician, STD clinic staff members drew two vials of blood from all patients who visited the clinics (one for syphilis testing and one for confirmation of HIV, if needed). Clinic providers offered the HIV test to all patients; if accepted, providers requested the signed consent form required by the state of New York, and, when the oral fluid test was being used, they conducted the oral fluid rapid HIV test. Patients with reactive oral fluid tests were offered the fingerstick whole-blood test. The clinics were able to obtain confirmation of results for patients who refused the finger-stick test because the initially drawn tube of blood was sent routinely for Western blot confirmation of all reactive tests.
FIGURE 2. Number and percentage of positive and false-positive oral fluid and finger-stick whole-blood rapid human immunodeficiency virus (HIV) tests, as confirmed by serum Western blot results -New York City,* December 2005-May 2008
* Among patients tested in 10 sexually transmitted disease clinics. Of 31,122 patients tested during those 6 months, 213 (0.69%) reac tive oral fluid tests were false positive (specificity: 99.31%, below the lower limit of the CI of the manufacturer's specifications) compared with 231 (0.70%) reactive oral fluid tests confirmed positive by Western blot. Conse quently, in late May, because results from rapid tests per formed on whole-blood specimens were consistently more accurate than those from oral fluid tests and because rapid testing of whole-blood specimens required fewer additional tests for confirmation of HIV infection, NYC DOHMH again discontinued use of oral fluid specimen testing in STD clinics. Finger-stick whole-blood specimen testing was reinstituted as the initial rapid HIV testing method. Oral fluid HIV testing data for May 2008, which became avail able only after discontinuation of oral fluid testing in the STD clinics, indicated that the recent increase in falsepositive oral fluid tests did not continue in May and the test's specificity with oral fluid specimens (99.89%) was within the CI of the manufacturer's specifications; how ever, rapid HIV testing of oral fluid specimens has not resumed.
Reported by: J Cummiskey, MPH, M Mavinkurve, MPH, R PanethPollak, MPH, J Borrelli, MPH, A Kowalski, MPH, Bur of Sexually Transmitted Disease Control, New York City Dept of Health and Mental Hygiene. S Blank, MD, B Branson, MD, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC.
Editorial Note: Both the number of patients tested for HIV and the percentage who receive their test results have increased since rapid HIV testing was introduced in the New York City STD clinics in 2004. Nationally, public health laboratories report that rapid tests overall and oral fluid tests specifically account for an increasing proportion of all HIV tests (2), and patients are substantially more likely to receive rapid test results than conventional test results (3). The New York City data in this report under score the importance of routinely comparing reactive rapid test results with confirmatory Western blot test results as an essential component of quality assurance in HIV testing (4) . Several other jurisdictions have noted clusters of falsepositive oral fluid rapid HIV tests since an initial report from Minnesota in 2004 (5) (6) (7) (8) . Although the causes of these clusters of false-positive tests remain unexplained (6), investigations are under way to determine which specific factors (e.g., test device, site, operator, or oral fluid charac teristics of specific patients) might be associated with increased numbers of false-positive test results. Several pro grams have adopted strategies similar to the one used in New York City and are immediately repeating the rapid test on whole-blood specimens from patients who have reactive oral fluid tests. Other strategies under investigation include repeat testing with a second rapid test from a different manufacturer (9) .
The specificity of OraQuick rapid tests performed on oral fluid specimens is lower than that of OraQuick rapid tests performed on whole-blood specimens (5) . The test manufacturer's 99.8% specificity estimate with oral fluid is based on a clinical trial of 3,682 participants. In New York City STD clinics, performing approximately 5,000 oral fluid tests per month for 3 years, overall specificity has been 99.73%, but the month-to-month specificity has ranged from 98.88% to 99.98%. Although specificity was lower than the manufacturer's claim during certain months, the test's performance in the New York City clinics was not below the Food and Drug Administration (FDA) mini mum threshold of 98% for rapid HIV tests. § Because the prevalence of positive HIV tests has decreased among STD clinic patients concomitant with the increas ing number of tests, a slight increase in the percentage of reactive rapid tests that are determined to be false positive (decreased positive predictive value) was expected. How ever, this change does not account for recurrent clusters of false-positive tests.
The advantages of rapid HIV tests, particularly with oral fluid specimens, include increased availability and accept ability of testing among populations at high risk for HIV infection and increased receipt of test results among those tested (3). The strategy used in New York City, with immediate follow-up using a retest on whole-blood speci mens, allowed the STD clinics to continue oral fluid rapid testing while mitigating, somewhat, the adverse effects of false-positive results on both patients and clinic personnel. The strategy also allowed health department staff mem bers to detect the increase in false-positive tests promptly, avert the majority of instances in which patients might have left the clinic with an oral fluid test result only (e.g., with § (10) . The New York City data indicate that repeating a rapid test on fingerstick whole blood after receiving a reactive oral fluid test result allows clinic counselors to provide more accurate testresult information to patients while minimizing the num ber of finger-stick tests that must be performed. Regardless, confirmatory testing is required to confirm both oral fluid and whole-blood reactive rapid HIV tests. Before testing, all patients should be informed that reactive rapid HIV test results are preliminary and require confirmation. In general, testing with blood or serum specimens is more accurate than testing with oral fluid and is preferred when feasible, especially in settings where blood specimens already are obtained routinely.
Overall, oral fluid rapid tests have performed well and make HIV testing possible in many venues where perform ing phlebotomy or finger sticks is impractical for screen ing. However, users should be aware of the unexplained variability in the rate of false-positive test results. CDC will continue to work with FDA and the manufacturer to investigate the causes and extent of increases in falsepositive oral fluid tests, monitor the performance of oral fluid and other rapid tests to ensure that they continue to perform as expected in testing programs, and investigate other combination test strategies to minimize falsepositive test results. Table II . § § Updated monthly from reports to the Division of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention. Implementation of HIV reporting influences the number of cases reported. Updates of pediatric HIV data have been temporarily suspended until upgrading of the national HIV/AIDS surveillance data management system is completed. Data for HIV/AIDS, when available, are displayed in Table IV , which appears quarterly. ¶ ¶ Updated weekly from reports to the Influenza Division, National Center for Immunization and Respiratory Diseases. Eighty-four cases occurring during the 2007-08 influenza season have been reported. *** No measles cases were reported for the current week. † † † Data for meningococcal disease (all serogroups) are available in Table II . § § § In 2008, Q fever acute and chronic reporting categories were recognized as a result of revisions to the Q fever case definition. Prior to that time, case counts were not differentiated with respect to acute and chronic Q fever cases. ¶ ¶ ¶ No rubella cases were reported for the current week. **** Updated weekly from reports to the Division of Viral and Rickettsial Diseases, National Center for Zoonotic, Vector-Borne, and Enteric Diseases.
MMWR
June 20, 2008 -12  26  86  380  -0  0  ---0  0  --Puerto Rico  -113  612  3, 1  9  19  189  170  19  24  63  598  501  -1  4  32  38  Washington  -9  87  111  170  -50  142  17  1,771  -0  3  2  1 American Samoa -5  51  110  95  5  17  134  294  373  1  2  23  20  40  Arkansas§   -0  1  3  6  -1  3  16  34  -0  2  2  6  Louisiana  -0  3  4  15  -1  8  14  44  -0  2  -1  Oklahoma  -0  7  4  3  3  2  37  38  20  1  0  3  3  1  Texas§   -5  49  99  71  2  12  110  226  275  -1  18  15  32   Mountain  -4  10  97  119  5  3  7  78  111  1  2  6  40  34  Arizona  -2  8  43  84  -1  4  18  49  -1  5  12  9  Colorado  -0  3  19  17  -0  3  10  17  -0  2  3  7  Idaho§   -0  3  1 4  2  -0  2  4  5  1  0  1  2  3  Montana§   -0  2  -2  -0  1  ---0  1  2  1  Nevada§   -0  1  3  7  -1  3  19  26  -0  2  6  3  New Mexico§   -0  3  1 4  3  -0  2  6  8  -0  1  3  3  Utah  -0  2  2  2  5  0  2  19  4  -0  3  12  5  Wyoming§   -0  1  2  2  -0  1  2  2  -0  0  -3   Pacific  5  13  51  289  314  4  9  29  160  230  1  4  18  110  48  Alaska  -0  1  2  2  -0  2  7  4  -0  1  1  -California  5  10  42  237  282  4  6  19  112  174  1  3  14  87  38  Hawaii  -0  2  4  3  -0  2  3  5  -0  1  4  1  Oregon§   -1  3  19  13  -1  4  20  27  -0  2  7  3  Washington  -1  7  27  14  -1  9  18  20  -0  3  11  6 American Samoa Table I . § Contains data reported through the National Electronic Disease Surveillance System (NEDSS). 47  59  221  789  1,337  6  5  15  88  96  1  3  7  79  83  Delaware  17  12  34  274  272  -0  1  1  2  -0  0  -1  District of Columbia  -2  9  43  48  -0  1  -2  -0  0  --Florida  2  0  4  12  2  3  1  7  27  20  -1  5  30  30  Georgia  -0  3  3  3  -1  3  19  13  -0  3  9  9  Maryland§   24  29  136  343  759  1  1  5  25  27  1  0  2  9  17  North Carolina  -0  8  2  14  -0  2  2  12  -0  4 3  4  8  100  25  3  3  10  57  59  4  4  17  148  140  Alaska  -0  2  1  2  -0  2  2  2  -0  2  3  1  California  3  2  8  95  21  3  2  8  45  41  4  3  17  110  102  Hawaii  N  0  0  N  N  -0  1  2  2  -0  2  1  4  Oregon§   -0  1  4  2  -0  2  4  9  -1  3  2 0  1 9  Washington  -0  7  ---0  3  4  5  -0  5  14  14 American Samoa 1  6  14  133  131  -1  11  8  15  -1  6  24  26  Washington  -12  103  190  219  -1  13  19  29  -2  20  29  46 American Samoa - N  N  2  8  17  191  142  Kentucky  -1  4  38  17  -0  2  8  2  2  1  7  44  33  Mississippi  -0  0  ---0  0  ---2  15  60  54  Tennessee§   1  4  12  113  65  -1  3  19  14  10  7  14  172  128 W.S. Central  -1  5  25  49  -0  2  6  7  20  40  60  900  755  Arkansas§   -0  2  8  1  -0  1  2  2  -2  10  52  52  Louisiana  -0  5  17  48  -0  2  4  5  -11  22  189  206  Oklahoma  N  0  0  N  N  N  0  0  N  N  -1  5  35  31  Texas§   -0  0  ---0  0  --20  26  47  624  466   Mountain  -1  6  17  26  -0  2  4  9  1  8  29  120  189  Arizona  -0  0  ---0  0  ---3  21  24  99  Colorado  -0  0  ---0  0  ---1  7  48 -13  42  326  428  -0  5  -1  -0  2  --Louisiana  -1  7  27  86  -0  5  ---0  3  --Oklahoma  N  0  0  N  N  -0  11  ---0  8  1  -Texas¶   161  159  894  5,068  6,431  -0  19  -3  -0  11  2  3  Mountain  13  38  105  1,181  1,720  -0  36  1  3  -0  148  -9  Arizona  -0  0  ---0  8  1  2  -0  10  --Colorado  6  16  43  542  667  -0  17  ---0 ---------------Guam  -2  17  54  165  -0  0  ---0  0  --Puerto Rico  -11  37  243  411  -0  0  ---0 for California serogroup, eastern equine, Powassan, St. Louis, and western equine diseases are available in Table I . Not notifiable in all states. Data from states where the condition is not notifiable are excluded from this table, except in 2007 for the domestic arboviral diseases and influenzaassociated pediatric mortality, and in 2003 for SARS-CoV. Reporting exceptions are available at http://www.cdc.gov/epo/dphsi/phs/infdis.htm. ¶ Contains data reported through the National Electronic Disease Surveillance System (NEDSS).
S. Atlantic
- 0 2 - 3 - 0 2 - - - 0 2 2 4 Montana § - 0 2 - 1 - 0 1 - 2 - 0 1 4 1 Nevada § - 0 2 - 6 - 0 3 4 1 - 0 2 6 3 New Mexico § - 0 2 - - - 0 1 - 1 - 0 1 4 2 Utah - 0 1 - 1 - 0 3 - 8 - 0 2 2 7 Wyoming § - 0 1 - - - 0 0 - - - 0 1 2 2
Pacific
N 0 0 N N - 0 0 - - - 0 0 - - C.N.M.I. - - - - - - - - - - - - - - - Guam - 0 0 - - - 0 1 1 - - 0 0 - - Puerto Rico N 0 0 N N - 0 1 1 1 - 0 1 2 5 U.S. Virgin Islands N 0 0 N N - 0 0 - - - 0 0 - - C.N.- 0 0 - - N 0 0 N N American Samoa - 0 0 - - N 0 0 N N N 0 0 N N C.N.M.I. - - - - - - - - - - - - - - - G u a m - 0 0 - - - 0 0 - - N 0 0 N N Puerto Rico - 0 0 - - - 10 1 1 - - 0 0 - - - 0 1 1 3 C.N.M.I. - - - - - - - - - - - - - - - G u a m - 0 2 5 1 1 - 0 0 - - - 0
